Accueil

La principale fonction du Groupe Dépistage du CIRC consiste à produire des données sur l'exactitude, la reproductibilité, l'efficacité, les avantages, les effets néfastes et la rentabilité de diverses interventions de dépistage précoce pour les cancers du sein, du col utérin, et pour les cancers colorectal et buccal, entre autres, en faisant baisser la mortalité et en améliorant la qualité de vie des patients dans différents contextes. Ces données peuvent ensuite être utilisées pour informer et améliorer l'utilisation rationnelle des ressources de soins de santé. L'objectif ultime du Groupe est de guider l'élaboration de politiques de santé publique pour la mise en œuvre du dépistage dans divers contextes de soins de santé, notamment dans les pays à revenu faible ou intermédiaire (PRFI).

Le Groupe SCR mène des études de terrain dans les PRFI pour évaluer diverses méthodes de détection précoce dans la lutte contre les cancers du sein, du col utérin, et les cancers colorectal et buccal. Ces initiatives visent aussi à identifier la façon dont les services de dépistage pourraient être intensifiés par le biais des services de santé publique au niveau local. Le Groupe développe diverses ressources de formation pour catalyser et renforcer les capacités en étroite collaboration avec les institutions nationales et les services de santé du gouvernement. Grâce à son programme de recherche, le Groupe apporte des bases scientifiques factuelles pour soutenir l'élaboration de politiques de détection précoce et de systèmes de santé appropriés pour la prestation de services primaires efficaces. Par exemple, le Groupe a contribué de manière significative à l'évaluation de l'innocuité et de l'efficacité d’un régime de moins de trois doses du vaccin contre le VPH pour la protection contre le cancer du col de l'utérus.


Actualité

Publication of IARC Handbooks of Cancer Prevention Volume 18: Cervical Cancer Screening

06/05/2022
This publication is an important update of the previous IARC Handbook on cervical cancer screening (Volume 10, published in 2005). Volume 18 provides evidence-based evaluations of the effectiveness of five methods of cervical cancer screening in reducing cervical cancer incidence and/or mortality. The Working Group also reviewed the body of evidence and provided conclusive statements on the comparative effectiveness of those screening methods that are established to reduce cervical cancer incidence and/or mortality. In addition, the Working Group provided an updated literature review on the determinants of participation in screening programmes and on emerging techniques, as well as on the different categories of women at differential risk and the surveillance strategies for such women.
View the publication.

Training for non-radiologist clinicians to perform breast ultrasound and manage lesions suspicious of cancer

02/05/2022 – 06/05/2022
Within the framework of the project, Evaluation of a portable ultrasound device to triage the women positive on clinical breast examination by trained healthcare workers and medical officers, organized in Kannur, India by the Malabar Cancer Society in collaboration with BARC and IARC, staff involved in this project were trained to perform breast ultrasound on CBE positive women and learn to differentiate features of benign breast lesions from the suspicious and malignant ones.

Principal investigators meeting: SaveCervix

29/04/2022 – 30/04/2022
In collaboration with the All India Institute of Medical Sciences (New Delhi, India), the Cancer Institute (WIA) Chennai (Chennai, India), and the Chittaranjan National Cancer Institute (CNCI) (Kolkata, India), the Early Detection, Prevention & Infections Branch/IARC organized today the SAVE-Cervix PI meeting in Kolkata, India to discuss about the development and evaluation of an artificial intelligence (AI) image recognition device to improve cervical pre-cancer screening and management in low- and middle-income countries. View the SAVE-Cervix research summary page.

New publication: Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study

28/04/2022
New article was published in the Journal of International Journal of Cancer. The triage performance and predictive value of human gene methylation panel alone and with combination of HPV16/18 genotyping were evaluated based on a prospective cohort with 1,758 women with positive result for hrHPV on self-collected samples. The results revealed that the triage performance of the methylation panel alone or in combination with HPV16/18 had satisfactory balance between sensitivity and specificity. Moreover, the negative result of above triage conferred the substantial low 3-year risk of incident CIN 2+. View the article.

Principal investigators meeting for the HPV vaccination study to evaluate the effectiveness of one, two, and three doses of quadrivalent HPV vaccine in preventing cervical neoplasia, Delhi, India

19/04/2022 – 21/04/2022
The Screening Group organized this meeting for all principal investigators, programme managers, and key collaborators from the study sites involved in this project, to discuss Data and Safety Monitoring Board (DSMB) recommendations, study progress, and recent findings.

Toutes les actualités


Publications scientifiques

Banerjee D., Mittal S., Mandal R., Basu P. Screening technologies for cervical cancer: Overview. Cytojournal. 2022 Mar 29;19:23. doi: 10.25259/CMAS_03_04_2021.
PMID: 35510117
Benider A., Bendahhou K., Sauvaget C., Mrabti H., Selmouni F., Muwonge R., Alaoui L., Lucas E., Chami Y., Abousselham L., Bennani M., Errihani H., Sankaranarayanan R., Bekkali R., Basu P. Evolution of patterns of care for women with cervical cancer in Morocco over a decade. BMC Cancer. 2022 May 2;22(1):479.
PMID: 35501742
Zhang L., Zhao X., Hu S., Chen S., Zhao S., Dong L., Carvalho A.L., Muwonge R., Zhao F., Basu P. Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: results from a prospective cohort study. Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34041.
PMID: 35460075

Toutes les publications scientifiques

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© CIRC 2022 - Terms of use  -  Politique de confidentialité.